Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
Edgewise Therapeutics (Nasdaq: EWTX) announced that COO Behrad Derakhshan, Ph.D. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 3:00 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) announced that COO Behrad Derakhshan, Ph.D. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 3:00 pm ET. The presentation will be webcast live and available for limited replay via the company Events & Presentations page.
Details
News Market Reaction – EWTX
On Feb 5, the day this news came out, EWTX closed 4.50% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Summit date
- February 12, 2026
- Guggenheim Emerging Outlook: Biotech Summit 2026 presentation date
- Presentation time
- 3:00 pm ET
- Scheduled time for Edgewise Therapeutics presentation webcast
- Announcement date
- Feb. 5, 2026
- Press release date for Guggenheim Summit presentation notice
Historical Context
-
Stock option inducement grants to new non‑executive employees under 2024 plan.
-
Outlined 2026 priorities, pivotal trial milestones, and funded development via follow‑on.
-
Announcement of presentation at the 44th J.P. Morgan Healthcare Conference.
-
Inducement stock option grants to new employees with time‑based vesting.
-
Favorable Phase 2 CIRRUS‑HCM data for EDG‑7500 with safety and efficacy signals.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn and X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-present-at-the-guggenheim-emerging-outlook-biotech-summit-2026-on-february-12-2026-302679536.html
SOURCE Edgewise Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.